… in advanced EGFR-mutant non–small cell lung cancer (… TKIs inevitably develop acquired
resistance by mechanisms that … the unique characteristic of resistance mechanisms acquired …

… mechanisms require precise diagnostics and elicit a wide portfolio of different and effective
… efficacy of EGFR-Tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers have …

… EGFR) tyrosine kinase inhibitors (TKIs), has revolutionized the treatment of this frequently
occurring lung … mutation-positive non-small cell lung cancer (NSCLC). The first-generation TKIs …

… While a frequently utilized strategy for combating acquired resistance to EGFR TKIs remains
… Results of a separate cohort of the phase 1 CHRYSALIS trial show antitumor activity in …

… Additionally, we discuss the acquired resistance … 2% of EGFR-mutant NSCLCs exposed to
osimertinib (Table 2), both in the first- and second-line settings [8,26,27]. Several different 5′ …

… (EGFR) are treated with specific tyrosine kinase inhibitors (… escape cell death in different
types of cancer, please refer to … in EGFR-mutant NSCLC models with acquired resistance to …

… Second-line treatments that target an acquired resistance … with acquired resistance to first-
or second-generation EGFR … DTCs arise from different pre-existing cell lineages with distinct …

… Baseline characteristics were not significantly different between the two cohorts after PSM. …
mutations can gain survival benefits from multiple generation tyrosine kinase inhibitors (TKIs…

… First-generation EGFR tyrosine kinase inhibitors (TKIs), such … with EGFR-mutant NSCLC.
Recently, the third-generation … be different from those in acquired and subclonal EGFR T790M -…

… EGFR-mutated NSCLC with acquired resistance to first-line … T790M and C797S mutations
on different alleles, called trans-… penetration profile in an EGFR-mutant brain metastasis model …